Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytek Biosciences, Inc.CTKB · Entity 5345 | SVP BUS. AND CORP. DEV. | November 18, 2024 | November 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytek Biosciences, Inc.
Report date November 18, 2024 · Filed November 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,981 |
Ending reported balance
After 2024-11-18 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2024-11-18 · Exercise / conversion · Acquired 790 · Balance 57,615 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2024-11-18 · Tax withholding · Disposed 308 · Balance 57,307 F2: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 3 · 2024-11-18 · Exercise / conversion · Acquired 2,503 · Balance 59,810 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 4 · 2024-11-18 · Tax withholding · Disposed 975 · Balance 58,835 F2: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 5 · 2024-11-18 · Exercise / conversion · Acquired 1,878 · Balance 60,713 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 6 · 2024-11-18 · Tax withholding · Disposed 732 · Balance 59,981 F2: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 3,693 |
Reported balance
After 2024-11-18 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-11-18 · Exercise / conversion · Disposed 790 · Balance 3,693 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 23,368 |
Reported balance
After 2024-11-18 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-11-18 · Exercise / conversion · Disposed 2,503 · Balance 23,368 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 25,048 |
Reported balance
After 2024-11-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-11-18 · Exercise / conversion · Disposed 1,878 · Balance 25,048 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
F3: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18.
F4: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested.
F5: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2023 Filed May 19, 2023 18:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,669 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-031246 · doc4.xml · nonDerivative · entry 3 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 18, 2023 Filed May 19, 2023 18:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 308 | $6.69 | $2,060.52 |
DisclosureSEC source: 0001209191-23-031246 · doc4.xml · nonDerivative · entry 2 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,190 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 18, 2023 Filed May 19, 2023 18:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 790 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-031246 · doc4.xml · nonDerivative · entry 1 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 19:50 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 40,056 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016980 · doc4.xml · derivative · entry 2 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,056 Underlying: Common Stock · 40,056 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 19:50 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,541 | $0.00 Strike: $10.61 | $0.00 |
DisclosureSEC source: 0001209191-23-016980 · doc4.xml · derivative · entry 1 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,541 Underlying: Common Stock · 60,541 shares Expires 2033-03-03 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over four years from the vesting commencement date of March 3, 2023. The option becomes fully vested on March 3, 2027. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 18:45 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 790 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-012357 · doc4.xml · derivative · entry 3 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,223 Underlying: Common Stock · 790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 18:45 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 308 | $10.97 | $3,378.76 |
DisclosureSEC source: 0001209191-23-012357 · doc4.xml · nonDerivative · entry 2 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,708 F3 · shares: Represents the number of shares withheld by and surrendered to the Issuer on February 21, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 18:45 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 790 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-012357 · doc4.xml · nonDerivative · entry 1 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 237 shares acquired by the Reporting Person under the Issuer's 2021 Employee Stock Purchase Plan on November 30, 2022. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 18:02 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 790 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-058465 · doc4.xml · derivative · entry 3 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,013 Underlying: Common Stock · 790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 18:02 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 308 | $14.75 | $4,543.00 |
DisclosureSEC source: 0001209191-22-058465 · doc4.xml · nonDerivative · entry 2 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,989 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 18:02 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 790 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-058465 · doc4.xml · nonDerivative · entry 1 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 19:39 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 790 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046948 · doc4.xml · derivative · entry 3 Poirson Allen · CIK 0001874301 · SVP Marketing and Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,803 Underlying: Common Stock · 790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 19:39 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 308 | $14.06 | $4,330.48 |
DisclosureSEC source: 0001209191-22-046948 · doc4.xml · nonDerivative · entry 2 Poirson Allen · CIK 0001874301 · SVP Marketing and Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,507 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 19:39 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 790 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-046948 · doc4.xml · nonDerivative · entry 1 Poirson Allen · CIK 0001874301 · SVP Marketing and Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 18, 2022 Filed May 20, 2022 19:17 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,053 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-031170 · doc4.xml · derivative · entry 3 Poirson Allen · CIK 0001874301 · SVP Marketing and Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,593 Underlying: Common Stock · 1,053 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| May 18, 2022 Filed May 20, 2022 19:17 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 411 | $9.65 | $3,966.15 |
DisclosureSEC source: 0001209191-22-031170 · doc4.xml · nonDerivative · entry 2 Poirson Allen · CIK 0001874301 · SVP Marketing and Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,025 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 18, 2022 Filed May 20, 2022 19:17 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,053 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-031170 · doc4.xml · nonDerivative · entry 1 Poirson Allen · CIK 0001874301 · SVP Marketing and Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 18:00 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 12,646 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015006 · doc4.xml · derivative · entry 2 Poirson Allen · CIK 0001874301 · SVP Marketing and Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,646 Underlying: Common Stock · 12,646 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 18:00 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantStock Option (Right to Buy) · Derivative | 19,081 | $0.00 Strike: $13.64 | $0.00 |
DisclosureSEC source: 0001209191-22-015006 · doc4.xml · derivative · entry 1 Poirson Allen · CIK 0001874301 · SVP Marketing and Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,081 Underlying: Common Stock · 19,081 shares Expires 2032-02-28 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly over four years from the vesting commencement date of January 1, 2022. The option becomes fully vested on January 1, 2026. Read SEC document |
| July 22, 2021 Filed Jul 26, 2021 21:49 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-048267 · doc4.xml · derivative · entry 1 Poirson Allen · CIK 0001874301 · SVP Marketing and Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-07-22 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vests on July 22, 2022; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years. Read SEC document |
| July 22, 2021 Filed Jul 27, 2021 20:59 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | PurchaseCommon Stock | 1,500 | $17.00 | $25,500.00 |
DisclosureSEC source: 0001209191-21-048386 · doc4.xml · nonDerivative · entry 1 Poirson Allen · CIK 0001874301 · SVP Marketing and Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,383 F1 · shares: Reflects shares purchased from the underwriters in the Company's initial public offering. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.